Acute urinary morbidity following I-125 prostate brachytherapy
- 62 Downloads
In Japan, iodine-125 (I-125) prostate brachytherapy has been legally approved since July 2003, and this method is becoming more popular. The purpose of the present study was to assess acute urinary morbidity within the first 6 months after I-125 prostate brachytherapy.
A group of 130 consecutive patients with loca-lized prostate cancer was treated with I-125 prostate brachytherapy between September 2003 and June 2004,either alone (monotherapy; 66 patients) or in combination with external-beam radiotherapy (combined therapy; 64 patients). Urinary morbidity was evaluated using the National Cancer Institute – Common Terminology Criteria for Adverse Events, version 3.0.
During the follow-up, 111 patients (85.4%) developed some degree of urinary symptoms such as frequency, retention, dysuria, incontinence, or hematuria. Urinaryfrequency (73.1%) and retention (66.9%) were the most common, and showed no significant differences between the monotherapy group and combined therapy group (P = 0.352 and P = 0.630, respectively). Six patients (4.6%) required catheterization for urinary obstruction; the median timeto onset was 1.5 days (range, 1–192 days). Five of these6 patients received monotherapy and the other received combined therapy.
Manifestations of acute urinary morbidity, especially frequency and retention, are relatively common but acceptable events after I-125 prostate brachytherapy.
Key wordsProstate cancer Brachytherapy Iodine-125 Urinary morbidity Catheterization
Unable to display preview. Download preview PDF.
- 1.Pasteau, O, Degrais, P 1914The radium treatment of cancer of the prostateArch Roentgenol Ray18396410Google Scholar
- 14.Fleming, D American Joint Committee on Cancer, NationalCancer Institute (US) et al. 1997AJCC cancer staging manualLippincott-RavenPhiladelphiaGoogle Scholar
- 16.Ragde, H, Elgamal, AA, Snow, PB, et al. 1998Ten-year disease-free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinomaCancer839891001CrossRefPubMedGoogle Scholar
- 20.Mallick, S, Azzouzi, R, Cormier, L, et al. 2003Urinary morbidity after 125I brachytherapy of the prostateBr J Urol92555558Google Scholar